- Menu
- 1. Lymphomes en 2020: au-delà de la chimiothérapie
- 2. Cas clinique
- 3. Classification des lymphomes
- 4. On some morbid appeaances of the absorbent glands and spleen
- 5. Classification WHO 2016
- 6. Perspectives historiques
- 7. Sarcoma and Hodgkin's disease
- 8. Nitrogen mustard therapy
- 9. Cancer research - Adriamycin
- 10. Combination chemotherapy (MOPP) in the management of advenced Hodgkin's disease
- 11. Combination chemotherapy of Hodgkin's disease with ABVD versus MOPP
- 12. Adriamycin combination chemotherapy in malignant lymphoma
- 13. Progrès récent remarquables
- 14. Chronologie
- 15. Classification / moléculaire
- 16. Classification (suite)
- 17. A predictive model for aggressive non-Hodgkin's lymphoma
- 18. Distinct tyoes of diffuse large B-cell lymphoma identified by gene expression profiling
- 19. Confirmation of the molecular classification
- 20. Genetics and pathogenesis of Diffuse Large B-cell Lymphoma
- 21. Articles
- 22. Thérapeutique
- 23. Hodgkin
- 24. Brentuximab vedotin as consolidation therapy
- 25. Brentuximab vedotin with chemotherapy
- 26. PD-1 blockade with nivolumab in relapsed of refractory Hodgkin's lamphoma
- 27. DLBCL
- 28. Chop chemotherapy plus rituximab compared with chop alons
- 29. Comparaison of a standard regimen (CHOP) with three intensive chemotherapy
- 30. Autologous transplantation as consolidation for agressive non-hodgkin's lymphoma
- 31. Tisagenlecleucel in adult relapsed or refractory iffuse Large B-cell lymphoma
- 32. CAR
- 33. Conclusions
- 34. Conclusions (suite)